{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:05:54Z","timestamp":1790719554153,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1136\/ijgc-2022-004190","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T10:30:20Z","timestamp":1674815420000},"page":"598-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Myeloid neoplasms post PARP inhibitors for ovarian cancer"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct04644068","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1936","authenticated-orcid":false,"given":"Giuseppe","family":"Caruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Parma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Lapresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Derio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocenza","family":"Palaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-004190_bb0010","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1136\/ijgc-2022-004190_bb0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"key":"10.1136\/ijgc-2022-004190_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100033","article-title":"Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome\/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database","volume":"6","author":"Ma","year":"2021","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2022-004190_bb0030","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-004190_bb0035","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-004190_bb0040","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0045","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-004190_bb0050","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-004190_bb0055","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-004190_bb0060","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0065","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","article-title":"Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer","volume":"162","author":"Matulonis","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0070","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.645","article-title":"517O Overall survival (OS) at 7-year (Y) follow-up (f\/u) in patients (PTS) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1\/GOG-3004 trial","volume":"33","author":"DiSilvestro","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0080","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0085","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1200\/JCO.2018.36.15_suppl.5548","volume":"36","author":"Korach","year":"2018","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-004190_bb0090","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1136\/ijgc-2022-004190_bb0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejca.2021.08.016","article-title":"Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy","volume":"157","author":"Matsuo","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2022-004190_bb0100","article-title":"Myelodysplastic syndrome\/acute myeloid leukemia following the use of poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1136\/ijgc-2022-004190_bb0105","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1136\/ijgc-2022-004190_bb0110","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.annonc.2021.04.015","article-title":"Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights","volume":"32","author":"Martin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.33269","article-title":"Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: a single-center experience","volume":"148","author":"Todisco","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-004190_bb0120","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/ijc.34162","article-title":"Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes","volume":"151","author":"Todisco","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-004190_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00607-7","article-title":"Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series","volume":"12","author":"Oliveira","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1136\/ijgc-2022-004190_bb0130","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.1002\/ajh.26697","article-title":"A common pattern of somatic mutations in t-MDS\/AML of patients treated with PARP inhibitors for metastatic ovarian cancer","volume":"97","author":"Chiusolo","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1136\/ijgc-2022-004190_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246385","article-title":"PARP inhibitors and myeloid neoplasms: a double-edged sword","volume":"13","author":"Csizmar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2022-004190_bb0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/ijgc-2022-004190_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2022-004190_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2022.01.024","article-title":"Efficacy and safety of olaparib according to age in BRCA1\/2-mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2\/ENGOT-ov21 study","volume":"165","author":"Trillsch","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1136\/ijgc-2022-004190_bb0160","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","article-title":"Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States","volume":"151","author":"Shenolikar","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1136\/ijgc-2022-004190_bb0175","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jnci\/djab231","article-title":"Clonal hematopoiesis-associated gene mutations in a clinical cohort of 448 patients with ovarian cancer","volume":"114","author":"Weber-Lassalle","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-004190_bb0180","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1136\/ijgc-2022-004190_bb0185","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/jamaoncol.2021.4664","article-title":"Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib","volume":"7","author":"Kwan","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0190","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","author":"Shu","year":"2022","journal-title":"Cancer Med"},{"key":"10.1136\/ijgc-2022-004190_bb0195","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1136\/ijgc-2022-004190_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5612","article-title":"AGO-OVAR 28\/ENGOT-ov57: niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer\u2014A multicenter, randomized, phase III trial","volume":"40","author":"Heitz","year":"2022","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-004190_bb0210","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: a meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0215","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0220","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J Med Chem"},{"key":"10.1136\/ijgc-2022-004190_bb0225","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2022-004190_bb0230","series-title":"LBA29 final overall survival (OS) results from the phase III PAOLA-1\/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)","author":"Ray-Coquard","year":"2022"},{"key":"10.1136\/ijgc-2022-004190_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.646","article-title":"518O Overall survival results from ARIEL4: a phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1\/2 mutation","volume":"33","author":"Oza","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0240","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0090-8258(22)01244-6","article-title":"Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1- and\/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)","volume":"166","author":"Penson","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0245","article-title":"2022-RA-249-ESGO overall survival results from ARIEL3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","volume":"32","author":"Coleman","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-004190_bb0250","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-004190_bb0255","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.658","article-title":"530P PRIMA\/ENGOT-OV26\/GOG-3012 study: updated long-term PFS and safety","volume":"33","author":"Gonzalez Martin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0265","doi-asserted-by":"crossref","first-page":"S1396","DOI":"10.1016\/j.annonc.2022.08.025","article-title":"LBA29 Final overall survival (OS) results from the phase III PAOLA-1\/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)","volume":"33","author":"Ray-Coquard","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004190_bb0270","doi-asserted-by":"crossref","first-page":"v351","DOI":"10.1093\/annonc\/mdx372.058","article-title":"OReO\/ENGOT Ov-38: a phase IIIB trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer","volume":"28","author":"Pujade-Lauraine","year":"2017","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-004190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:14Z","timestamp":1753234154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24024459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1048891X24024459"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-004190","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid neoplasms post PARP inhibitors for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-004190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}